NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q3 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,883 | +434.4% | 36,741 | +416.0% | 0.00% | – |
| Q2 2023 | $4,095 | -97.5% | 7,120 | -96.9% | 0.00% | – |
| Q1 2023 | $163,000 | +37544.3% | 232,486 | +21.7% | 0.00% | – |
| Q4 2022 | $433 | -99.9% | 191,003 | -17.2% | 0.00% | – |
| Q3 2022 | $738,000 | -70.9% | 230,620 | -65.4% | 0.00% | – |
| Q2 2022 | $2,533,000 | +157.2% | 666,570 | +265.0% | 0.00% | – |
| Q1 2022 | $985,000 | +5.3% | 182,638 | +164.0% | 0.00% | – |
| Q4 2021 | $935,000 | -77.7% | 69,173 | -70.3% | 0.00% | -100.0% |
| Q3 2021 | $4,190,000 | +4.0% | 233,295 | -0.7% | 0.00% | – |
| Q2 2021 | $4,029,000 | -10.5% | 234,832 | +4.3% | 0.00% | -100.0% |
| Q1 2021 | $4,503,000 | +50.3% | 225,124 | +27.7% | 0.00% | – |
| Q4 2020 | $2,997,000 | -16.0% | 176,247 | -16.5% | 0.00% | -100.0% |
| Q3 2020 | $3,567,000 | -27.6% | 211,149 | -0.8% | 0.00% | 0.0% |
| Q2 2020 | $4,928,000 | +49.8% | 212,834 | +15.5% | 0.00% | 0.0% |
| Q1 2020 | $3,290,000 | -91.7% | 184,281 | -90.0% | 0.00% | -85.7% |
| Q4 2019 | $39,679,000 | +26.5% | 1,838,262 | +6.7% | 0.01% | +16.7% |
| Q3 2019 | $31,372,000 | -39.8% | 1,722,279 | +14.7% | 0.01% | -40.0% |
| Q2 2019 | $52,081,000 | -28.8% | 1,501,770 | -31.0% | 0.01% | -33.3% |
| Q1 2019 | $73,099,000 | +26.0% | 2,175,528 | +23.3% | 0.02% | +15.4% |
| Q4 2018 | $57,994,000 | -40.8% | 1,764,312 | +9.8% | 0.01% | -31.6% |
| Q3 2018 | $97,959,000 | -6.2% | 1,606,950 | -24.9% | 0.02% | -9.5% |
| Q2 2018 | $104,461,000 | -22.4% | 2,139,269 | +68.9% | 0.02% | -27.6% |
| Q1 2018 | $134,622,000 | +40.4% | 1,266,915 | -21.1% | 0.03% | +45.0% |
| Q4 2017 | $95,903,000 | +74.2% | 1,605,866 | -30.9% | 0.02% | +66.7% |
| Q3 2017 | $55,040,000 | +24.9% | 2,324,346 | +3.1% | 0.01% | +20.0% |
| Q2 2017 | $44,062,000 | -33.1% | 2,253,793 | -19.7% | 0.01% | -33.3% |
| Q1 2017 | $65,891,000 | +353.7% | 2,807,422 | +137.2% | 0.02% | +400.0% |
| Q4 2016 | $14,523,000 | +20.6% | 1,183,582 | +68.8% | 0.00% | 0.0% |
| Q3 2016 | $12,043,000 | -3.1% | 700,979 | -19.7% | 0.00% | 0.0% |
| Q2 2016 | $12,426,000 | +1.3% | 873,233 | -2.1% | 0.00% | 0.0% |
| Q1 2016 | $12,266,000 | -28.8% | 892,142 | -12.8% | 0.00% | -25.0% |
| Q4 2015 | $17,230,000 | +64.6% | 1,022,549 | +7.1% | 0.00% | +33.3% |
| Q3 2015 | $10,470,000 | -13.1% | 955,206 | -0.9% | 0.00% | 0.0% |
| Q2 2015 | $12,053,000 | -75.9% | 963,560 | -78.8% | 0.00% | -72.7% |
| Q1 2015 | $50,013,000 | -33.6% | 4,546,714 | -6.5% | 0.01% | -35.3% |
| Q4 2014 | $75,362,000 | +41.0% | 4,862,029 | +9.8% | 0.02% | +30.8% |
| Q3 2014 | $53,453,000 | -5.1% | 4,428,675 | +0.8% | 0.01% | -7.1% |
| Q2 2014 | $56,306,000 | +2.2% | 4,392,052 | -3.3% | 0.01% | -6.7% |
| Q1 2014 | $55,071,000 | +170.0% | 4,543,898 | +152.9% | 0.02% | +150.0% |
| Q4 2013 | $20,394,000 | +2.0% | 1,796,845 | -6.2% | 0.01% | 0.0% |
| Q3 2013 | $20,002,000 | -18.6% | 1,914,973 | -10.0% | 0.01% | -25.0% |
| Q2 2013 | $24,563,000 | – | 2,126,777 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |